Novavax (NVAX)
(Delayed Data from NSDQ)
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
Pre-Market: $9.31 -0.04 (-0.43%) 8:14 AM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.35 USD
-0.26 (-2.71%)
Updated Nov 1, 2024 04:00 PM ET
Pre-Market: $9.31 -0.04 (-0.43%) 8:14 AM ET
2-Buy of 5 2
D Value A Growth D Momentum B VGM
Zacks News
Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study
by Zacks Equity Research
Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.
Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
5 Biotech Stocks Up More Than 100% This Year So Far
by Zacks Equity Research
Here we discuss five biotech companies recording impressive growth so far in 2020.
Biotech Stock Roundup: GILD Gets CRL, REGN Collaborates With RHHBY & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Novavax Begins Phase IIb Coronavirus Vaccine Study in South Africa
by Zacks Equity Research
Novavax (NVAX) starts a phase IIb study in South Africa to evaluate the efficacy of its COVID-19 vaccine candidate NVX-CoV2373. Shares rise following this development.
Company News for Aug 18, 2020
by Zacks Equity Research
Companies In The News Are: DPZ, NVAX, JD, CRTX.
Company News for Aug 17, 2020
by Zacks Equity Research
Companies in the news are: AMAT, MESO, NVAX, SKYS
Encompass Health's Buyout Spree on Track, PPE Costs High
by Zacks Equity Research
Encompass Health (EHC) continues to benefit from buyouts and cash generating abilities. However, increased PPE utilization is worrisome.
Novavax (NVAX) to Supply Coronavirus Vaccine to UK Government
by Zacks Equity Research
Novavax (NVAX) enters an agreement to provide the UK government with 60 million doses of its COVID-19 vaccine, NVX-CoV2373, if approved.
FUJIFILM (FUJIY) Q1 Earnings Top Estimates, Revenues Drop Y/Y
by Zacks Equity Research
FUJIFILM's (FUJIY) fiscal first-quarter results reflect coronavirus impact on the top line and operating income.
Should You Invest in COVID Themed ETFs?
by Neena Mishra
We highlight three new ETFs that seek to capitalize on coronavirus
Novavax's (NVAX) Earnings Beat in Q2, Sales Lag Estimates
by Zacks Equity Research
Novavax's (NVAX) loss narrows for the second quarter of 2020 but revenues miss the mark.
Novavax (NVAX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Novavax (NVAX) delivered earnings and revenue surprises of 47.37% and -21.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novava, Veritone, Kopin, Quidel and Unum Therapeutics
Is Novavax (NVAX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NVAX) Outperforming Other Medical Stocks This Year?
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More
by Kinjel Shah
Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.
Nasdaq Tops 11,000: 5 Best Stocks With Room for More Upside
by Sweta Killa
On Aug 6, the Nasdaq Composite Index topped the milestone of 11,000. The tech-heavy laden completed its 1000-point journey in 40 trading days, representing the fastest ever rise in 20 years.
Stock Market News for Aug 6, 2020
by Zacks Equity Research
Wall Street closed higher on Wednesday supported by some developments regarding Congressional negotiations on a second round of fiscal stimulus.
Novavax (NVAX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $146.62, marking a +0.87% move from the previous day.
Will Novavax (NVAX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Late-Stage Coronavirus Vaccine Trials Begin: Biotech ETFs to Gain
by Sweta Jaiswal, FRM
Two major vaccine developers' entrance into the final stage trials is expected to boost investor optimism.
Coronavirus Vaccine Efforts Key to Novavax (NVAX) Q2 Earnings
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. While increased clinical activity is expected to have increased expenses, pipeline development grants may have offered some respite in Q2 earnings.
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
What's in Store for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Pfizer, Moderna, Vaxart and Novovax